Andy Snyder


Andy trained in the laboratory from 2015-2016 as a Research Scientist.

During his time in the lab, he was supported by Broad-Bayer collaboration.

A key research contribution during this period of training was leading target validation efforts on genes associated with early-onset MI.

Andy is currently Principal Scientist at Twenty-eight Seven Therapeutics.

Leave a Comment